ea0050oc2.4 | Clinical Highlights | SFEBES2017
Mitsaki Stefania
, Flynn Michael
, Gore Martin
, Larkin James
, Morganstein Daniel
Background: Immune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, demonstrating durable responses, but can result in immune-related adverse events (irAEs). Endocrinopathies are amongst the more common adverse events, and thyroid dysfunction and hypophysitis being the most frequent; the latter of these has been positively correlated with oncological outcome. This study compared overall survival (OS), progression-free survival (PFS) and disease c...